Clostridium Difficile Clinical Trial
— FMTOfficial title:
Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection (CDI) in Pediatric and Young Adult Patients
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon. Investigators believe that putting more "good" bacteria into the colon will help fight the "bad" bacteria. We do this by doing a fecal (poop) transplant. Fecal transplant has been done at other hospitals, but not at Nationwide Children's Hospital. Since our Investigators have not done this before, this study will help us learn the best way to do the transplant. Investigators also believe this transplant might help improve symptoms for patients with C-diff.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 21 Years |
Eligibility | Inclusion Criteria: Recipient inclusion criteria: - Documented laboratory-confirmed clostridium difficile infection - Documentation of ongoing diarrhea at time of recruitment - Children =2 years old, <18 years old; young adults >18 years old, <21 years old - Undergoing clinically-indicated colonoscopy - Recurrent c-diff infection (three or more occurrences) Donor inclusion criteria: - First-degree relative recommended, but not compulsory - = 18 years old - In good health - No antibiotic use within the last 90 days - In "low risk" category on modified DHQ (See above) Exclusion Criteria: - Recipient exclusion criteria - Severe comorbid condition (at discretion of the principal investigator) - On immunosuppressive medications (high dose steroids 30 mg/kg of methylprednisolone) - Severe or fulminant C. difficile colitis - Toxic appearance - Signs of hemodynamic instability - Peritoneal signs on physical exam - Anemia on complete blood count - electrolyte imbalances on basic metabolic panel - Considerations for Increased Risk of Adverse Events Should Be Given to patients with decompensated liver cirrhosis, advanced HIV/acquired immune deficiency syndrome, recent bone marrow transplant, or other cause of severe immunodeficiency. - History of severe anaphylactic shock Donor exclusion criteria: - Abnormal stools - Abdominal complaints - History of inflammatory bowel disease or gastrointestinal malignancy - Symptoms indicative of irritable bowel syndrome or other chronic pain syndromes (e.g. chronic fatigue syndrome, fibromyalgia) - History of systemic autoimmunity (e.g. multiple sclerosis, connective tissue disease) - Recent use of potent immunosuppressive medications (calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc..) - Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s) - Known communicable disease - Neurologic, neurodevelopmental or neurodegenerative disorders - History of malignancy - Has consumed any foods/medications to which the recipient is allergic within the designated period of time |
Country | Name | City | State |
---|---|---|---|
United States | GI Division, Nationwide Children's Hospital | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Jonathan Gisser |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Resolution of C. difficile | The primary objective of the study is to establish the cure rate of C. difficile infection in pediatric patients. | 6 months post transplant | |
Secondary | Adverse events | Follow up phone calls will be made at days 1, 7, 14, and months 1 and 6 to determine whether adverse events have occurred. | Six months post transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02896244 -
AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment
|
||
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Recruiting |
NCT01973465 -
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
|
N/A | |
Terminated |
NCT01048567 -
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
|
Phase 2 | |
Completed |
NCT01066221 -
Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile
|
N/A | |
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Completed |
NCT02563106 -
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
|
Phase 2 | |
Completed |
NCT02857582 -
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
|
Phase 2 | |
Completed |
NCT02207140 -
Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly
|
Phase 0 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT01703494 -
Fecal Transplant for Relapsing C. Difficile Infection
|
Phase 2 | |
Completed |
NCT01813500 -
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01087892 -
Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection
|
N/A | |
Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
Recruiting |
NCT00377078 -
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.
|
N/A | |
Completed |
NCT02254967 -
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
|
Phase 4 | |
Terminated |
NCT01775397 -
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
|
Phase 4 | |
Terminated |
NCT03617172 -
PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol
|
Phase 2 | |
Recruiting |
NCT05622721 -
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
|
||
Completed |
NCT02437487 -
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
|
Phase 2 |